On September 8, 2025 Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, reported that it has received an expanded CE Mark approval for SIR-Spheres Y-90 resin microspheres for the treatment of patients with liver cancer (Press release, Sirtex Medical, SEP 8, 2025, View Source [SID1234655839]). With this expansion, eligibility now covers both primary and secondary liver metastases, increasing patient access to a well-established, targeted therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This milestone is about more than regulatory approval—it’s about giving hope and options back to patients facing some of the toughest cancer diagnoses," said Matt Schmidt, CEO of Sirtex Medical. "By expanding access to SIR-Spheres, we’re ensuring that more people can benefit from a well-tolerated therapy when they need it most."

Radioembolization—also known as selective internal radiation therapy (SIRT)—delivers yttrium-90 directly to tumors via the hepatic artery, allowing for high-dose, targeted radiation aiming to minimize impact to surrounding healthy tissue.

"Y-90 radioembolization has long demonstrated clinical value in managing complex liver tumors," said Prof. Dr. med. Jens Ricke, Director of the Clinic and Polyclinic of Radiology at the University Hospital Ludwig-Maximilians in Munich, Germany. "With this expanded CE Mark, more patients will have access to a therapy that can extend life, improve quality of life, and offer hope when other treatments may no longer be effective."

The CE Mark expansion follows an extensive review of clinical data demonstrating the safety and effectiveness of SIR-Spheres across diverse liver metastases. Together with the FDA’s recent approval of SIR-Spheres Y-90 resin microspheres for the treatment of unresectable HCC in the United States, this milestone underscores the growing global recognition of SIR-Spheres as a versatile, differentiated therapy and reinforces the Sirtex commitment to advancing liver-directed interventional oncology.